Chugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 52-Week High – Time to Buy?

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $26.00 and last traded at $24.76, with a volume of 1000911 shares. The stock had previously closed at $24.49.

Chugai Pharmaceutical Price Performance

The company has a market cap of $81.44 billion, a P/E ratio of 36.01 and a beta of 0.89. The stock has a fifty day moving average price of $23.54 and a two-hundred day moving average price of $19.45.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.22 earnings per share (EPS) for the quarter. The business had revenue of $2.03 billion during the quarter. Chugai Pharmaceutical had a net margin of 32.68% and a return on equity of 21.45%. Equities analysts predict that Chugai Pharmaceutical Co., Ltd. will post 0.78 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.